Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Doctoral Research Award - PA: Drug Safety and Effectiveness

Université de Montréal

$105,000.00

Assessment of poor INR control, bleeding events and thrombosis among patients initiating warfarin: The Quebec Warfarin Cohort Study (QWCS)

FY 2014-15

Summary
Warfarin is a commonly oral anticoagulant prescribed for prevention of blood clots. Patients taking this drug should be monitored closely since the required dose may vary up to 20 fold between some patients. A dose that is too high can increase the time required to coagulate, to such an extent that patients can suffer major bleeding. This is an ongoing problem that is worsening as the population ages and eligible patients increase in numbers. Moreover, preliminary results of our study demonstrate that patients who are poorly stabilized have higher rates of bleeding requiring a hospitalization (10.3%) than patients moderately stabilized (4.2%) and patients highly stable (2.8%). In the present study, we will use data from a prospective cohort study to investigate clinical, lifestyle and genetic predictors of a poor stabilization, bleeding events and blood clotting events related to warfarin treatment. A total of 1,069 patients have been recruited within 19 hospitals in the province of Quebec and were followed-up each three months up to one year after initiation of warfarin therapy. DNA analysis were performed to assess genetic risk factors (CYP2C9 and VKORC1 genes). Data collected will help targeting patients at high risk of poor control, bleeding and blood clotting who may benefit of new oral anticoagulants. Optimizing the management of anticoagulant therapy may not only improve the prevention of bleeding and clotting, but also provide a considerable health and quality of life benefit and decrease in associated health-care costs.
Program
Doctoral Research Award - PA: Drug Safety and Effectiveness
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
317869
Name
Dumas Stephanie
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Population and Public Health
Theme2
Clinical
Prcname2
Doctoral Research Awards - A
Projecttitle
Assessment of poor INR control, bleeding events and thrombosis among patients initiating warfarin: The Quebec Warfarin Cohort Study (QWCS)
Programtype2
Studentship Programs
Orgnameinp2
Université de Montréal
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Research Award - PA: Drug Safety and Effectiveness
Keyworddelim
Anticoagulant; Biostatistic; Bleeding; Haemorrhagic Events; International Normalized Ratio (Inr) Fluctuations; Pharmacoepidemiology; Pharmacogenetic; Prospective Cohort Study; Warfarin
Abstract
Warfarin is a commonly oral anticoagulant prescribed for prevention of blood clots. Patients taking this drug should be monitored closely since the required dose may vary up to 20 fold between some patients. A dose that is too high can increase the time required to coagulate, to such an extent that patients can suffer major bleeding. This is an ongoing problem that is worsening as the population ages and eligible patients increase in numbers. Moreover, preliminary results of our study demonstrate that patients who are poorly stabilized have higher rates of bleeding requiring a hospitalization (10.3%) than patients moderately stabilized (4.2%) and patients highly stable (2.8%). In the present study, we will use data from a prospective cohort study to investigate clinical, lifestyle and genetic predictors of a poor stabilization, bleeding events and blood clotting events related to warfarin treatment. A total of 1,069 patients have been recruited within 19 hospitals in the province of Quebec and were followed-up each three months up to one year after initiation of warfarin therapy. DNA analysis were performed to assess genetic risk factors (CYP2C9 and VKORC1 genes). Data collected will help targeting patients at high risk of poor control, bleeding and blood clotting who may benefit of new oral anticoagulants. Optimizing the management of anticoagulant therapy may not only improve the prevention of bleeding and clotting, but also provide a considerable health and quality of life benefit and decrease in associated health-care costs.
Competitiondate
201410
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Dumas, Stephanie
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~
Université de Montréal - $105,000 Grant (2014-15) | Canada Spends